{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:01:19Z","timestamp":1790996479854,"version":"4.1.0"},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,5,26]],"date-time":"2010-05-26T00:00:00Z","timestamp":1274832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tumor necrosis factor (TNF)\u2010\u03b1 is a pro\u2010inflammatory cytokine that plays an important role in the pathogenesis of a variety of autoimmune diseases. TNF\u2010\u03b1 inhibitors have been shown to offer clinical benefits in the treatment of autoimmune and inflammatory disorders, including rheumatoid arthritis, ankylosing spondylitis (AS), and Crohn\u2019s disease. Occasionally, these agents have been associated with infectious complications because of their immunosuppressive activity. Globally, several cases of infections associated with TNF\u2010\u03b1 inhibitors have been reported. However, <jats:italic>Aspergillus<\/jats:italic> infection associated with etanercept is very rare. We report a case of chronic necrotizing pulmonary aspergillosis in a 51\u2010year\u2010old man with AS that developed after treatment with etanercept.<\/jats:p>","DOI":"10.1111\/j.1756-185x.2010.01528.x","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T06:48:40Z","timestamp":1274942920000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor\u2010\u03b1 inhibitor"],"prefix":"10.1111","volume":"13","author":[{"given":"Eun Jung","family":"LEE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"SONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u2010Na","family":"PARK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon\u2010Ah","family":"LEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Seong","family":"SON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung\u2010Jae","family":"HONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung\u2010In","family":"YANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang\u2010Hoon","family":"LEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,3]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11301"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.4078\/jkra.2007.14.3.242"},{"key":"e_1_2_4_4_2","unstructured":"FDA(2001)Safety update on TNF\u2010\u03b1 antagonists: infliximab and etanercept. Food and Drug Administration Center for Biologics Evaluation and Research. Arthritis Advisory Committee Meeting August 17 2001."},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.9.1181"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2001.5183"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.4065\/83.2.181"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M201683200"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/429998"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02309.x"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6942(02)00107-9"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198203000-00005"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.6.1988"},{"key":"e_1_2_4_14_2","first-page":"2","volume-title":"Fisherman\u2019s Pulmonary Disease and Disorders","author":"Sugar AM","year":"1998"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2010.01528.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-185X.2010.01528.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:02:48Z","timestamp":1698750168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-185X.2010.01528.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1756-185X.2010.01528.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2010.01528.x","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"2010-08-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}